Anlon Healthcare Showcases Global Reach and Growth in Q2/H1 FY26 Investor Presentation

Anlon Healthcare Limited , a Gujarat-based pharmaceutical intermediates and APIs manufacturer, has released its Q2/H1 FY26 investor presentation, highlighting its expanding global presence and robust financial performance. The company, which operates across 15 countries, has demonstrated significant growth in its operations and financial metrics.

Operational Highlights

Anlon Healthcare boasts a manufacturing capacity of 400 MTPA, currently operating at an impressive 84.41% utilization rate. The company has strengthened its regulatory footprint by filing 21 Drug Master Files (DMFs) with global regulatory authorities, signaling its commitment to quality and compliance in the international pharmaceutical market.

Financial Performance

The company's financial results for Q2 and H1 FY26 showcase substantial year-on-year growth:

Particulars (In INR Cr)	Q2 FY25	Q2 FY26	Growth (%)	H1 FY25	H1 FY26	Growth (%)
Total Income	24.21	52.23	115.74%	62.11	85.53	37.71%
EBITDA	7.57	13.77	81.90%	14.55	20.01	37.53%
PAT	2.59	9.32	259.85%	6.36	12.86	102.20%
EPS (In INR)	0.41	2.22	441.46%	2.56	3.07	19.92%

The company has shown remarkable improvement across all key financial metrics, with Q2 FY26 showing particularly strong growth compared to the same quarter in the previous year.

Balance Sheet Strength

As of H1 FY26, Anlon Healthcare's balance sheet reflects a solid financial position:

Net Worth: INR 214.32 Cr
Total Assets: INR 309.48 Cr
Current Assets: INR 287.51 Cr

The company's improved financial standing is further evidenced by its reduced long-term borrowings, which decreased from INR 38.36 Cr in FY25 to INR 30.86 Cr in H1 FY26.

Market Position

Anlon Healthcare's stock performance on the BSE as of the presentation date:

Share Price: INR 146.00
Market Capitalization: INR 776.01 Cr
52-Week High/Low: INR 149.50 / INR 86.98

Strategic Initiatives

The company has outlined several strategic moves to enhance its market position:

Targeting 10-15 global DMF filings in the next 5 years to expand its regulatory footprint.
Focusing on cost management and operational efficiencies to drive profitability.
Entering the Industrial and Fine chemicals business, marking a diversification strategy.
Aiming to strengthen its balance sheet with a INR 5.00 Cr allocation.

Leadership Enhancement

Anlon Healthcare has recently bolstered its leadership team:

Anandbhai Natwerlal Katkoria joined as a Non-Executive Non-Independent Director in August 2024, bringing over 20 years of banking sector experience.
Kannepalli Krishna Murty, a Chartered Accountant with 25 years of experience, joined as a Non-Executive Independent Director in August 2024, enhancing the company's financial governance.

Anlon Healthcare's Q2/H1 FY26 investor presentation underscores the company's strong growth trajectory, operational efficiency, and strategic initiatives aimed at expanding its global presence in the pharmaceutical intermediates and APIs market. The company's focus on regulatory compliance, coupled with its robust financial performance, positions it well for continued growth in the competitive pharmaceutical sector.

1 Day	5 Days	1 Month	6 Months	1 Year	5 Years
+0.27%	+11.74%	+25.77%	+72.24%	+72.24%	+72.24%

Anlon Healthcare Limited has reported impressive financial results for the quarter ended September 30, 2025, demonstrating significant growth across key metrics.

Financial Highlights

The company's Q2 performance shows substantial year-over-year improvements:

Revenue from operations increased to Rs. 3,329.20 lacs, up from Rs. 2,416.63 lacs in the previous year's quarter, representing a 37.8% growth.
Profit after tax rose to Rs. 931.73 lacs, compared to Rs. 359.60 lacs year-over-year.

Half-Year Performance

For the half-year period:

Revenue reached Rs. 6,199.88 lacs, up from Rs. 5,355.74 lacs in the previous period.
Profit after tax increased to Rs. 1,286.42 lacs, compared to Rs. 635.58 lacs previously.

Company Overview

Anlon Healthcare Limited, a pharmaceutical manufacturer specializing in Active Pharmaceutical Ingredients (APIs) and drug intermediates, has been listed on the stock exchanges since September 3, 2025.

Financial Position

Total assets increased to Rs. 28,751.92 lacs from Rs. 18,848.09 lacs as of March 31, 2025.
The company has utilized Rs. 8,245.45 lacs from its IPO proceeds of Rs. 12,103.00 lacs, with Rs. 3,857.55 lacs remaining unutilized.

Anlon Healthcare's strong Q2 performance reflects its robust position in the market and its ability to capitalize on growth opportunities. The significant increase in revenue and profit demonstrates the company's effective strategies and market demand for its products.